EdgarLookup

ROKU, INC — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that ROKU, INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
1.9%
Profit Margin
Net income ÷ revenue
2%
Return on Assets
Net income ÷ assets
0.67x
Debt-to-Equity
Total liabilities ÷ equity
+15.2%
Revenue Growth
Year over year

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $4.74B Feb 13, 2026
FY2025 Dec 31, 2024 $4.11B Feb 13, 2026
FY2025 Dec 31, 2023 $3.48B Feb 13, 2026
FY2024 Dec 31, 2022 $3.13B Feb 14, 2025
FY2023 Dec 31, 2021 $2.76B Feb 16, 2024
FY2020 Dec 31, 2020 $649.89M Feb 26, 2021
FY2020 Sep 30, 2020 $451.66M Feb 26, 2021
FY2020 Jun 30, 2020 $356.07M Feb 26, 2021
FY2020 Mar 31, 2020 $320.77M Feb 26, 2021
FY2020 Dec 31, 2019 $411.23M Feb 26, 2021

Revenue (Net Sales)

Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.

Fiscal Year Period End Value Filed
FY2017 Dec 31, 2017 $188.26M Mar 1, 2018
FY2017 Sep 30, 2017 $124.78M Mar 1, 2018
FY2017 Jun 30, 2017 $99.63M Mar 1, 2018
FY2017 Mar 31, 2017 $100.09M Mar 1, 2018
FY2017 Dec 31, 2016 $147.34M Mar 1, 2018
FY2017 Oct 1, 2016 $89.05M Mar 1, 2018
FY2017 Jul 2, 2016 $83.81M Mar 1, 2018
FY2017 Apr 2, 2016 $78.45M Mar 1, 2018
FY2017 Dec 26, 2015 $319.86M Mar 1, 2018

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $2.07B Feb 13, 2026
FY2025 Dec 31, 2024 $1.81B Feb 13, 2026
FY2025 Dec 31, 2023 $1.52B Feb 13, 2026
FY2024 Dec 31, 2022 $1.44B Feb 14, 2025
FY2023 Dec 31, 2021 $1.41B Feb 16, 2024
FY2020 Dec 31, 2020 $305.46M Feb 26, 2021
FY2020 Sep 30, 2020 $214.82M Feb 26, 2021
FY2020 Jun 30, 2020 $146.84M Feb 26, 2021
FY2020 Mar 31, 2020 $141.10M Feb 26, 2021
FY2020 Dec 31, 2019 $161.65M Feb 26, 2021

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $88.36M Feb 13, 2026
FY2025 Dec 31, 2024 ($129.39M) Feb 13, 2026
FY2025 Dec 31, 2023 ($709.56M) Feb 13, 2026
FY2024 Dec 31, 2022 ($498.01M) Feb 14, 2025
FY2023 Dec 31, 2021 $242.39M Feb 16, 2024
FY2020 Dec 31, 2020 $67.31M Feb 26, 2021
FY2020 Sep 30, 2020 $12.95M Feb 26, 2021
FY2020 Jun 30, 2020 ($43.15M) Feb 26, 2021
FY2020 Mar 31, 2020 ($54.61M) Feb 26, 2021
FY2020 Dec 31, 2019 ($15.72M) Feb 26, 2021

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($5.62M) Feb 13, 2026
FY2025 Dec 31, 2024 ($218.17M) Feb 13, 2026
FY2025 Dec 31, 2023 ($792.38M) Feb 13, 2026
FY2024 Dec 31, 2022 ($530.89M) Feb 14, 2025
FY2023 Dec 31, 2021 $235.10M Feb 16, 2024
FY2022 Dec 31, 2020 ($20.25M) Feb 16, 2023
FY2021 Dec 31, 2019 ($65.06M) Feb 18, 2022
FY2020 Dec 31, 2018 ($13.30M) Feb 26, 2021
FY2019 Dec 31, 2017 ($19.62M) Mar 2, 2020
FY2018 Dec 31, 2016 ($43.36M) Mar 1, 2019

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $729.48M Feb 13, 2026
FY2025 Dec 31, 2024 $720.15M Feb 13, 2026
FY2025 Dec 31, 2023 $878.47M Feb 13, 2026
FY2024 Dec 31, 2022 $788.91M Feb 14, 2025
FY2023 Dec 31, 2021 $461.60M Feb 16, 2024
FY2022 Dec 31, 2020 $355.78M Feb 16, 2023
FY2021 Dec 31, 2019 $265.01M Feb 18, 2022
FY2020 Dec 31, 2018 $170.69M Feb 26, 2021
FY2019 Dec 31, 2017 $107.95M Mar 2, 2020
FY2018 Dec 31, 2016 $76.18M Mar 1, 2019

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $483.72M Feb 13, 2026
FY2025 Dec 31, 2024 $218.05M Feb 13, 2026
FY2025 Dec 31, 2023 $255.86M Feb 13, 2026
FY2024 Dec 31, 2022 $11.80M Feb 14, 2025
FY2023 Dec 31, 2021 $228.08M Feb 16, 2024
FY2022 Dec 31, 2020 $148.19M Feb 16, 2023
FY2021 Dec 31, 2019 $13.71M Feb 18, 2022
FY2020 Dec 31, 2018 $13.92M Feb 26, 2021
FY2019 Dec 31, 2017 $37.29M Mar 2, 2020
FY2018 Dec 31, 2016 ($32.46M) Mar 1, 2019

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $5.28M Feb 13, 2026
FY2025 Dec 31, 2024 $5.06M Feb 13, 2026
FY2025 Dec 31, 2023 $82.62M Feb 13, 2026
FY2024 Dec 31, 2022 $161.70M Feb 14, 2025
FY2023 Dec 31, 2021 $40.04M Feb 16, 2024
FY2022 Dec 31, 2020 $82.38M Feb 16, 2023
FY2021 Dec 31, 2019 $77.18M Feb 18, 2022
FY2020 Dec 31, 2018 $18.33M Feb 26, 2021
FY2019 Dec 31, 2017 $9.23M Mar 2, 2020
FY2018 Dec 31, 2016 $8.60M Mar 1, 2019

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $4.43B Feb 13, 2026
FY2025 Dec 31, 2024 $4.30B Feb 13, 2026
FY2024 Dec 31, 2023 $4.26B Feb 14, 2025
FY2023 Dec 31, 2022 $4.41B Feb 16, 2024
FY2022 Dec 31, 2021 $4.08B Feb 16, 2023
FY2021 Dec 31, 2020 $2.27B Feb 18, 2022
FY2020 Dec 31, 2019 $1.47B Feb 26, 2021
FY2019 Dec 31, 2018 $465.00M Mar 2, 2020
FY2018 Dec 31, 2017 $371.90M Mar 1, 2019
FY2017 Dec 31, 2016 $179.08M Mar 1, 2018

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $1.78B Feb 13, 2026
FY2025 Dec 31, 2024 $1.81B Feb 13, 2026
FY2024 Dec 31, 2023 $1.94B Feb 14, 2025
FY2023 Dec 31, 2022 $1.77B Feb 16, 2024
FY2022 Dec 31, 2021 $1.32B Feb 16, 2023
FY2021 Dec 31, 2020 $942.53M Feb 18, 2022
FY2020 Dec 31, 2019 $771.81M Feb 26, 2021
FY2019 Dec 31, 2018 $220.35M Mar 2, 2020
FY2018 Dec 31, 2017 $219.62M Mar 1, 2019
FY2017 Dec 31, 2016 $159.72M Mar 1, 2018

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $2.66B Feb 13, 2026
FY2025 Dec 31, 2024 $2.49B Feb 13, 2026
FY2025 Dec 31, 2023 $2.33B Feb 13, 2026
FY2025 Dec 31, 2022 $2.65B Feb 13, 2026
FY2024 Dec 31, 2021 $2.77B Feb 14, 2025
FY2023 Dec 31, 2020 $1.33B Feb 16, 2024
FY2022 Dec 31, 2019 $698.43M Feb 16, 2023
FY2021 Dec 31, 2018 $244.65M Feb 18, 2022
FY2020 Dec 31, 2017 $152.28M Feb 26, 2021
FY2019 Dec 31, 2016 ($193.82M) Mar 2, 2020

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $309.41M Feb 13, 2026
FY2025 Dec 31, 2024 $161.52M Feb 13, 2026
FY2024 Dec 31, 2023 $161.52M Feb 14, 2025
FY2023 Dec 31, 2022 $161.52M Feb 16, 2024
FY2022 Dec 31, 2021 $161.52M Feb 16, 2023
FY2022 Dec 31, 2020 $73.06M Feb 16, 2023
FY2021 Dec 31, 2019 $74.12M Feb 18, 2022
FY2020 Dec 31, 2018 $1.38M Feb 26, 2021
FY2018 Dec 31, 2017 $1.38M Mar 1, 2019

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($1.49B) Feb 13, 2026
FY2025 Dec 31, 2024 ($1.43B) Feb 13, 2026
FY2024 Dec 31, 2023 ($1.30B) Feb 14, 2025
FY2023 Dec 31, 2022 ($588.03M) Feb 16, 2024
FY2022 Dec 31, 2021 ($90.02M) Feb 16, 2023
FY2021 Dec 31, 2020 ($332.41M) Feb 18, 2022
FY2020 Dec 31, 2019 ($313.83M) Feb 26, 2021
FY2019 Dec 31, 2018 ($253.90M) Mar 2, 2020
FY2018 Dec 31, 2017 ($283.34M) Mar 1, 2019
FY2017 Dec 31, 2016 ($219.83M) Mar 1, 2018

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $1.59B Feb 13, 2026
FY2025 Dec 31, 2024 $2.16B Feb 13, 2026
FY2025 Dec 31, 2023 $2.03B Feb 13, 2026
FY2024 Dec 31, 2022 $1.96B Feb 14, 2025
FY2023 Dec 31, 2021 $2.15B Feb 16, 2024
FY2022 Dec 31, 2020 $1.09B Feb 16, 2023
FY2021 Dec 31, 2019 $515.48M Feb 18, 2022
FY2020 Dec 31, 2018 $155.56M Feb 26, 2021
FY2019 Dec 31, 2017 $177.25M Mar 2, 2020

Long-Term Debt

Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.

Fiscal Year Period End Value Filed
FY2019 Dec 31, 2018 $0 Mar 2, 2020
FY2018 Dec 31, 2017 $0 Mar 1, 2019

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 0 Feb 13, 2026
FY2025 Dec 31, 2024 0 Feb 13, 2026
FY2025 Dec 31, 2023 (5) Feb 13, 2026
FY2024 Dec 31, 2022 (3) Feb 14, 2025
FY2023 Dec 31, 2021 1 Feb 16, 2024
FY2020 Dec 31, 2020 0 Feb 26, 2021
FY2020 Sep 30, 2020 0 Feb 26, 2021
FY2020 Jun 30, 2020 0 Feb 26, 2021
FY2020 Mar 31, 2020 0 Feb 26, 2021
FY2021 Dec 31, 2019 0 Feb 18, 2022

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 0 Feb 13, 2026
FY2025 Dec 31, 2024 0 Feb 13, 2026
FY2025 Dec 31, 2023 (5) Feb 13, 2026
FY2024 Dec 31, 2022 (3) Feb 14, 2025
FY2023 Dec 31, 2021 1 Feb 16, 2024
FY2020 Dec 31, 2020 0 Feb 26, 2021
FY2020 Sep 30, 2020 0 Feb 26, 2021
FY2020 Jun 30, 2020 0 Feb 26, 2021
FY2020 Mar 31, 2020 0 Feb 26, 2021
FY2021 Dec 31, 2019 0 Feb 18, 2022

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 147.85M Feb 13, 2026
FY2025 Dec 31, 2024 145.91M Feb 13, 2026
FY2024 Dec 31, 2023 143.50M Feb 14, 2025
FY2023 Dec 31, 2022 140.03M Feb 16, 2024
FY2022 Dec 31, 2021 135.14M Feb 16, 2023
FY2021 Dec 31, 2020 128.00M Feb 18, 2022
FY2020 Dec 31, 2019 119.90M Feb 26, 2021
FY2019 Dec 31, 2018 109.77M Mar 2, 2020
FY2018 Dec 31, 2017 99.16M Mar 1, 2019
FY2017 Dec 31, 2016 4.82M Mar 1, 2018